.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for inclusion of people along with MASLD and measurement of liver outcomes in cardio-- renal-- metabolic trials, when data advise mechanistically possible benefits and also scientific safety-- as well as lays out considerations for trial style as well as regulative commendation.